BrECADD Therapy for Stage 2 B-IV Hodgkin Lymphoma
This study is looking at a treatment called BrECADD for people with Stage 2 B-IV Hodgkin Lymphoma (a type of cancer that affects the lymphatic system). The BrECADD treatment involves five different medications: Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, and Dacarbazine, given intravenously (into a vein) over four cycles. The main goal is to see how well this treatment works to prevent the cancer from growing or coming back. Researchers also want to explore if a blood test for circulating tumor DNA (ctDNA) can help understand how well the treatment is working. You may be able to join if you are between 18 and 60 years old and have been diagnosed with classical Hodgkin Lymphoma. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 48 participants. The phase of the study is not specified.
- What's involved
- Participants will receive intravenous medications on specific days over a 21-day cycle, for up to 4 cycles.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for progression-free survival for up to 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
At a glance
Conditions
NCT07002216
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Miami
Miami, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michele Stanchina, DO · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression-free survival (PFS)Up to 12 months
Progression-free survival (PFS) is defined as the elapsed time in months from the start of treatment until disease progression or death, whichever is earlier. Follow-up times for participants who remain alive without progression will be censored at the last documented disease assessment date.